Metabotropic glutamate receptors: Synaptic modulators and therapeutic targets for neurologic disease
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
AC= : adenylyl cyclase; DAG= : diacylglycerol; FMRP= : fragile X mental retardation protein; FXS= : fragile X syndrome; G= : guanine; GPCR= : guanine nucleotide binding protein coupled receptor; GPe= : external segment of the globus pallidus; GPi= : internal segment of the globus pallidus; IP3= : inositol triphosphate; LTD= : long-term depression; LTP= : long-term potentiation; mGluR= : metabotropic glutamate receptor; PKC= : protein kinase C; PLC= : phospholipase C; SNc= : substantia nigra pars compacta; SNr= : substantia nigra pars reticulata; STN= : subthalamic nucleus; SWD= : spike-and-wave discharges. Glutamate is the primary excitatory neurotransmitter in the CNS and acts via two main classes of receptors: ionotropic and metabotropic. Whereas ionotropic receptors are responsible for fast excitatory synaptic transmission, metabotropic glutamate receptors (mGluRs) have an important role in synaptic modulation throughout the CNS. Different subtypes of mGluRs regulate neuronal excitability, synaptic plasticity, neurotransmitter release, and glial functions, which are important for brain development and mechanisms of learning, injury, and neuroprotection.1–8 Not surprisingly, mGluRs have been implicated in the pathophysiology of several neurologic and psychiatric disorders, including hypoxic injury, epilepsy, Parkinson disease, Alzheimer disease, pain, anxiety, schizophrenia, and drug addiction. The development of selective non-competitive allosteric modulators of different subtypes of mGluRs allows elucidating the physiologic role of these receptors and their potential as therapeutic targets in neurologic disorders.9–11 This brief review focuses on the synaptic effects of mGluRs in some representative circuits and the potential clinical and therapeutic implications. Several publications provide a comprehensive coverage of these and related topics.1,3,5,8–16 The metabotropic receptors (mGluRs) are guanine nucleotide binding (G)-protein coupled receptors (GPCRs) that consist of dimers of subunits with seven transmembrane domains.1,2 There are eight subtypes of mGluRs that are classified, according to their structure, transduction mechanisms, and pharmacology into group I (mGluR1 and mGluR5), group II (mGlu2 and mGlu3), and group III (mGluR4, mGluR6, mGluR7, and mGluR8) receptors1–3 (table 1). Some of these receptors include several isoforms. View this table: Table 1 Overview of metabotropic glutamate receptors Group I receptors (mGluR1 and mGluR5) are positively coupled to phospholipase C, and trigger calcium (Ca2+) release from the endoplasmic reticulum and activation of protein kinase C. These receptors also potentiate l-type Ca2+ channels and inhibit K+ channels. Type I mGluRs may also act independently of G proteins to activate transducing cascades that trigger phosphorylation of …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
Metabotropic glutamate receptors as novel targets for anxiety and stress disorders
Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607
Glutamate‐mediated neuronal–glial transmission
Verkhratsky, A., & Kirchhoff, F. (2007) · Journal of Anatomy · doi:10.1111/j.1469-7580.2007.00734.x · Cited by 156
Cited by
Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5
Renner, M., Lacor, P. N., Velasco, P. T., Xu, J., Contractor, A., Klein, W. L., & Triller, A. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.029 · Cited by 468
Kufahl, P. R., Martin-Fardon, R., & Weiss, F. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.174 · Cited by 72
“mGluR2/3 are widely expressed throughout brain circuits that mediate ethanolassociated conditioned reinforcement, incentive motivation and reward (Dayas et al, 2007; Kenny and Markou, 2004; Tzschentke and Schmidt, 2003; Zhao et al, 2006), as well as circuits mediating stress and anxiety responses (Benarroch, 2008; Day…”
BackgroundInfluentialRole of paraventricular nucleus glutamate signaling in regulation of HPA axis stress responses
EVANSON, N. K., & HERMAN, J. P. (2015) · Interdisciplinary Information Sciences · doi:10.4036/iis.2015.b.10 · Cited by 48
G Protein-Coupled Receptor Heterocomplexes in Neuropsychiatric Disorders
Moreno, J. L., Holloway, T., & González-Maeso, J. (2013) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-386931-9.00008-8 · Cited by 30
Metadata
- Authors
- Benarroch, E. E.
- Venue
- Neurology
- Published
- 2008-03-18
- Volume
- 70
- Issue
- 12
- Pages
- 964-968
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2098673651
- Cited by
- 56
- References
- 3
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabotropic glutamate receptors: Synaptic modulators and therapeutic targets for neurologic disease. https://app.cochat.ai/papers/10.1212/01.wnl.0000306315.03021.2a
- The paper
- Benarroch, E. E. (2008). Metabotropic glutamate receptors: Synaptic modulators and therapeutic targets for neurologic disease. Neurology. https://doi.org/10.1212/01.wnl.0000306315.03021.2a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.